Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
This study will have two stages: dose finding stage and expansion stage. The Dose Finding stage will enrol people with advanced solid cancers, who will receive GDC-1971 (orally) once daily on Days 1-21 of each cycle, along with atezolizumab (1200mg, administered by intravenous infusion) once every 3 weeks. The Expansion Stage will enrol cohorts of participants with non-small cell lung cancer PD L-1high), non-small lung cancer PD L-1low, head and neck squamous cell carcinoma PDL-1 positive, BRAF wild type melanoma, and any locally advanced or metastatic solid cancers. In this stage, participants will receive GDC-1971 (orally) daily on Days 1-21 of each cycle, plus atezolizumab (1200mg, intravenously) on Day 1 of each cycle. Omeprazole will be administered orally in the acid-reducing agent assessment.